Navigation Links
Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In OvaScience, Inc. To Contact The Firm
Date:9/20/2013

NEW YORK, Sept. 20, 2013 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at OvaScience, Inc. ("OvaScience" or the "Company") (NASDAQ: OVAS).

(Logo: http://photos.prnewswire.com/prnh/20120119/MM38856LOGO)

The investigation focuses on whether the Company and its executives violated federal securities laws with respect to its disclosures concerning business, operational, and compliance policies.

Specifically, the investigation focuses on whether OvaScience misrepresented to the FDA and the investing public that its AUGMENT technology qualified for 361 HCT/P designation and therefore did not need FDA licensure in order to be tested and marketed.

On September 10, 2013, the Company announced that it would suspend enrollment of AUGMENT in the U.S. after receiving an "untitled" letter from the FDA questioning the designation of AUGMENT as 361 HCT/P. 

Following this news, OvaScience's stock declined by $3.32 or over 23%.

Request more information now by clicking here:  www.faruqilaw.com/OVAS.  There is no cost or obligation to you.

Take Action

If you invested in OvaScience stock or options between February 25, 2013 and September 10, 2013 and would like to discuss your legal rights, visit www.faruqilaw.com/OVAS.  You can also contact us by calling Richard Gonnello or Francis McConville toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com or fmcconville@faruqilaw.com.  Faruqi & Faruqi, LLP also encourages anyone with information regarding OvaScience's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

Attorney Advertising.  The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com).  Prior results do not guarantee or predict a similar outcome with respect to any future matter.  We welcome the opportunity to discuss your particular case.  All communications will be treated in a confidential manner.

FARUQI & FARUQI, LLP
369 Lexington Avenue, 10th Floor
New York, NY 10017
Attn:  Richard Gonnello, Esq.
rgonnello@faruqilaw.com
Francis McConville, Esq.
fmcconville@faruqilaw.com
Telephone: (877) 247-4292 or (212) 983-9330


'/>"/>
SOURCE Faruqi & Faruqi, LLP
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess of $100,000 Investing In Keryx Biopharmaceuticals, Inc. To Contact the Firm
2. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Neptune Technologies & Bioressources Inc. To Contact The Firm
3. Generex Provides Update on Generex Oral-lyn™ Clinical & Regulatory Program
4. The Law Firm of Levi & Korsinsky, LLP Launches an Investigation Into Possible Securities Laws Violations by Pacific Biosciences of California, Inc.
5. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
6. Chandler Chicco Companies Acquires Haas & Health Partner Public Relations and SanCom Creative Communication Solutions, Creating Unrivalled Healthcare Communication Capability in Germany
7. Generex Subsidiary Antigen Express Provides Update on AE37 Cancer Vaccines Clinical & Regulatory Strategy
8. Fifth Cycle of Probiotics & Microbiota Research Grant Announced
9. Hemodialysis Machine Industry 2012 Global & China Market Research Report - ReportsnReports
10. Aeras and CNBG Sign Agreement on Tuberculosis Vaccine R&D
11. Ikaria® to Present at 14th Annual BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2016)... North Carolina (PRWEB) , ... May 23, 2016 ... ... automation and building management solutions and services based in Aurora, Ohio, has broken ... of established business in the Research Triangle Park area, this new location solidifies ...
(Date:5/20/2016)... ... May 20, 2016 , ... Korean researchers say Manumycin ... may offer a new way to treat the disease. Surviving Mesothelioma has just posted ... , Scientists from several Korean institutions based their mesothelioma study on the fact the ...
(Date:5/19/2016)... ... May 19, 2016 , ... KCAS Bioanalytical and ... Siddiqui as Director, Large Molecule & Biomarker Bioanalysis. , Dr. Siddiqui has more ... discovery studies for preclinical and clinical safety programs. “We’ve seen significant demand for, ...
(Date:5/18/2016)... , May 18, 2016 The ... it does not mean that there are no opportunities ahead. ... Pharmaceuticals Inc. (NASDAQ: THLD ), Seattle Genetics Inc. ... CHMA ), and Ophthotech Corp. (NASDAQ: OPHT ). ... alerts at: http://www.activewallst.com/ Threshold ...
Breaking Biology Technology:
(Date:4/14/2016)... 2016 BioCatch ™, the ... announced the appointment of Eyal Goldwerger as ... Goldwerger,s leadership appointment comes at a time of ... deployment of its platform at several of the world,s ... discerns unique cognitive and physiological factors, is a winner ...
(Date:3/31/2016)... , March 31, 2016   ... ("LegacyXChange" or the "Company") LegacyXChange is excited ... of its soon to be launched online site for ... https://www.youtube.com/channel/UCyTLBzmZogV1y2D6bDkBX5g ) will also provide potential shareholders a ... DNA technology to an industry that is notorious for ...
(Date:3/29/2016)... Florida , March 29, 2016 ... the "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect are pleased ... in ink used in a variety of writing instruments, ... Buyers of originally created collectibles from athletes on LegacyXChange ... forensic analysis of the DNA. Bill ...
Breaking Biology News(10 mins):